Similar articles

• Long-term experience of alfacalcidol in renal osteodystrophy.

  Sharman VL, Brownjohn AM, Goodwin FJ, Hately W, Manning RM, O'Riordan JH, Papapoulos SE, Marsh FP. Sharman VL, et al. Q J Med. 1982 Summer;51(203):271-8. Q J Med. 1982. PMID: 7146311
• Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.

  Muirhead N, Adami S, Fraser RA, Catto GR, Edward N, O'Riordan JL. Muirhead N, et al. Proc Eur Dial Transplant Assoc. 1981;18:567-72. Proc Eur Dial Transplant Assoc. 1981. PMID: 6895786 No abstract available.
• Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy.

  Coburn JW, Brickman AS. Coburn JW, et al. Adv Exp Med Biol. 1978;103:473-86. doi: 10.1007/978-1-4684-7758-0_48. Adv Exp Med Biol. 1978. PMID: 362852 Review. No abstract available.
• The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.

  Junor BJ, Catto GR, Macleod M. Junor BJ, et al. Calcif Tissue Res. 1977 May;22 Suppl:112-6. doi: 10.1007/BF02064050. Calcif Tissue Res. 1977. PMID: 912512 No abstract available.
• The use of alfacalcidol in the prevention of bone disease in early renal failure.

  Kanis JA. Kanis JA. Nephrol Dial Transplant. 1995;10 Suppl 4:23-8; discussion 37-43. doi: 10.1093/ndt/10.supp4.23. Nephrol Dial Transplant. 1995. PMID: 7478146 Review. No abstract available.